Relief Therapeutics Secures Up to $11 Million from Royalty Sales

GENEVA (Aug. 5, 2024) – Relief Therapeutics Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) has signed and closed an agreement with SWK Funding LLC for the sale of royalty interests in OLPRUVA®, GOLIKE® and CAMBIA®, which will provide up to $11 million in cash.

This non-dilutive funding will support the advancement of Relief's pipeline, including the development of the hypochlorous acid topical spray, RLF-TD011, for epidermolysis bullosa. Additionally, the capital will be used for general corporate purposes and working capital.

Relief received an initial payment of $5.75 million and could receive an additional $5.25 million contingent on achieving specific milestones. Key milestones include $3.25 million if OLPRUVA achieves $1.5 million in quarterly net sales by Q3 2025, and $2 million upon U.S. FDA approval of arimoclomol for Niemann-Pick Disease Type C.

All future royalties and milestone payments from its agreements with Acer Therapeutics Inc. and Eton Pharmaceuticals Inc. are included in the arrangement. The agreement will terminate after SWK receives 2.75 times its investment.